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RECOMMENDATIONS FOR THE USE OF PATIENT REPORTED 
OUTCOMES TO ASSESS TREATMENT EFFICACY IN CLINICAL 
GUIDANCE DOCUMENTS RELEASED BY THE FDA AND EMEA
Arbuckle R1, Marquis P2, Caron M3, Emery MP3, Scott J1
1Mapi Values Ltd, Bollington, Cheshire, UK, 2Mapi Values, Boston, MA, USA, 3Mapi Research 
Trust, Lyon, France
OBJECTIVES: EMEA’s reﬂection paper on health related quality of life (HRQL) and 
FDA’s draft guidance on patient-reported outcomes (PRO) were published in 2006. 
Both discuss the use of PROs and HRQL, but leave questions about what PRO 
information regulators value for decision-making. The objective of this study was to 
use recent clinical guidance documents to understand and compare FDA and EMEA 
use of PRO endpoints for regulatory decisions. METHODS: PRO endpoints men-
tioned in clinical guidance documents published by the FDA and EMEA from January 
2006 through March 2009 were extracted. Analysis compared the number and nature 
of FDA and EMEA recommendations regarding PRO endpoints. RESULTS: PRO 
were mentioned in 12 FDA and 21 EMEA clinical guidance documents published 
between January 2006 and March 2009, reﬂecting 46% and 35% of the clinical 
guidance documents published by FDA and EMEA, respectively. FDA and EMEA each 
mentioned PRO symptom measures in nine clinical guidances, but HRQL was men-
tioned as an appropriate endpoint in only three FDA guidances compared with 16 
EMEA guidances. Speciﬁc PRO instruments were more often mentioned by name in 
EMEA guidance documents (11 EMEA vs. 1 FDA), but neither agency mandated a 
particular measure must be used. For both agencies, the level of detail provided regard-
ing recommendations for implementing PROs varied widely among guidances; typi-
cally, EMEA guidance on PRO endpoints was more detailed. Trends noted for 
indications and therapeutic areas will be presented. CONCLUSIONS: Clinical guid-
ance documents demonstrate that regulators value the patient perspective. FDA’s focus 
tends to be on PRO symptom assessment whereas EMEA often refers to HRQL and 
is more likely to specify instruments for PRO endpoints. These results indicate that 
FDA and EMEA use PRO-based evidence but the agencies differ in what type of PRO 
endpoints they encourage for regulatory decision-making.
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ADHERENCE OF PHARMACOECONOMIC STUDIES SUBMITTED FOR 
THE REIMBURSEMENT AND PRICING SYSTEM IN 2008 TO THE CZECH 
PHARMACOECONOMIC GUIDELINES
Petrikova A1, Dolezal T2, Suchankova E3
1University of Veterinary and Pharmaceutical Sciences Brno, Brno, Czech Republic, 2Charles 
University, Praha, Czech Republic, 3Charles University, Prague, Czech Republic
OBJECTIVES: To assess the quality of the health economic analysis (HEA) submitted 
for the reimbursement and pricing system in the Czech Republic in 2008. METHODS: 
Assessing quality of health economic guidelines (budget-impact analyses not included) 
submitted for the new molecules to the State Institute for Drug Control via the 
online system. The highly innovative medicines were excluded as for those entities       
there are no obligation to submit the HEA. The concordance with check-list of 
the Czech pharmacoeconomic guidelines (12 aspects of the HEA) was investigated. 
RESULTS: HEAs of 16 New Chemical Entities were investigated. A total of 87.5% 
of HEAs were submitted from the payer perspective, 18.8% from society perspective. 
The most common applied time horizon was 0–12 months (47%). Comparator        
was appropriately chosen in 81%. Analyses used were Cost-Utility analysis (47.6%), 
Cost-effectiveness analysis (28.6%) and Cost-Minimalisation analysis (23.8%). 
Models were used in 56% (including decision-tree, Markov and special models). 
The utility data were obtained from clinical trials (100%), Summary of Product 
Characteristic (SPC) (14%) and guidelines (7%). Data for the direct costs were 
obtained from price list of insurance companies (100%), published data (57%), 
etc. The most used type of costs were therapy, application, adverse side effects 
and in- and outpatient days. As an effectiveness measure QALYs were used in 43%, 
LYGs in 19% and surrogate clinical parameters in 38%). ICER was applied in 75%. 
Analysis of sensitivity was used only in 62.5%. Discounting of costs and outcomes 
was used in 56%; 67% of those used 3% discounting of both costs and outcomes. 
CONCLUSIONS: The assessment of the quality of the submitted HEA in the 
Czech Republic showed relatively short time horizon used, occasional problems with 
the choice of comparator, use of QALY in more then half HEA and insufﬁcient 
application of the analysis of sensitivity. The data from real-practice should be 
used more.
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COST-EFFECTIVENESS OF HEALTH PROMOTING INTERVENTIONS
De Smedt D1, Bakker M1, Annemans L2
1University of Ghent, Gent, Belgium, 2University of Ghent, Brussels University, Ghent, 
Belgium
OBJECTIVES: Recently, the Flemish government has formulated several health objec-
tives regarding healthy nutrition and physical exercise following recommendations 
from the WHO and the European Commission. The purpose of this study was to  
evaluate the cost-effectiveness of 16 potential health promoting interventions, related 
to these objectives. Interventions were aimed at the local community, the child environ-
ment, the workplace, health care providers and at information and communication 
channels. METHODS: A literature search was performed to determine the effective-
ness of the interventions on short term intermediate outcome parameters and on dia-
betes and cardiovascular and oncologic events. Afterwards modeling was performed 
to predict the expected lifetime results in avoided DALY’s. The simulation was carried            
out on 4 age categories, i.e. 40, 50, 60 and 70-years old, assuming a 10-year imple-
mentation of the intervention. For the interventions aimed at children, a projection 
was made to later adult life, based on literature. In addition, the investments required 
for implementing the interventions during a 10-year period, and the costs of avoided 
events were calculated from a societal perspective. This allowed calculating the Return 
On Investment (ROI) and the full beneﬁt cost ratio, assuming a value of a30,000 for 
avoiding one DALY. RESULTS: For the interventions aimed at the local community, 
the child environment, the workplace, health care providers and information and 
communication channels the average ROI equals to 9.59(1.32–22.44); 0.37(0.01–
1.68); 1.98(0.56–4.52); 9.25(2.71–17.20); and 58.02(14.72–125.55) Euro per invested      
euro respectively. About half of the interventions have a positive ROI. The average 
full beneﬁt cost ratio amounted to 36.36(5.89–71.36); 3.08(0.16–10.56); 9.14(3.33–
20.04); 37.24(15.97–54.54); and 233.63(86.64–398.17) respectively. Only two inter-
ventions (aimed at the child environment) appeared not to be cost-beneﬁcial for any 
age groups. CONCLUSIONS: Implementing interventions to promote a healthy life-
style could generate a substantial amount of health gain leading to very beneﬁcial 
beneﬁt/cost ratios for a majority of interventions.
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HOW DOES THE HEALTH IMPROVEMENT NETWORK (THIN) DATA  
ON PREVALENCE OF CHRONIC DISEASES COMPARE WITH  
NATIONAL FIGURES?
Blak BT, Thompson M
CSD EPIC, London, UK
OBJECTIVES: Primary care patient databases are increasingly used within many dif-
ferent research areas. These databases reﬂect everyday care provided to patients in a 
sample of practices. Thus, when used for research, information on generalisability 
to the general population is important. This study compared chronic condition 
prevalences from a UK primary care database, THIN, with national ﬁgures. 
METHODS: The study population was selected from THIN Data. The National 
Health Service (NHS) Quality and Outcomes Framework (QOF, a national standard 
used for the measurement of primary care outcomes for payment) disease/drug 
codelists and rules were used to derive crude prevalence of chronic diseases. Prevalence 
and 95% conﬁdence intervals (CIs) were derived as of February 14, 2007, March 
14, 2007, and April 1, 2007 from practices in Scotland/Northern Ireland, England, 
and Wales, respectively, to match QOF methodology. National QOF 2006/2007 
prevalence data were used for comparison. RESULTS: THIN population included 
2,783,593 people. The atrial ﬁbrillation crude prevalence was in THIN 1.42%(o0.01%) 
versus 1.31% nationally. For asthma these ﬁgures were 5.95%(o0.01%) versus 
5.79%, cancer 0.85%(o0.003%) versus 0.91%, coronary heart disease 3.89%(o0.01%) 
versus 3.67%, chronic kidney disease 2.48%(o0.02%) versus 2.33%, chronic obstruc-
tive pulmonary disease 1.57%(o0.01%) versus 1.48%, dementia 0.47%(o0.003%) 
versus 0.42%, diabetes 3.52%(o0.01%) versus 3.65%, epilepsy 0.63%(o0.002%) 
versus 0.62%, heart failure 0.88%(o0.004%) versus 0.80%, hypertension 
12.67%(o0.03%) versus 12.56%, learning disability 0.30%(o0.002%) versus 0.27%, 
mental health 0.74%(o0.004%) versus 0.72%, obesity 8.29%(o0.04%) versus 7.50%, 
palliative care 0.11%(o0.002%) versus 0.09%, stroke/transient ischaemic attack 
1.89%(o0.01%) versus 1.65%, hypothyroidism 2.74%(o0.01%) versus 2.63%. 
CONCLUSIONS: THIN and national crude prevalences were close but higher in 
THIN except for cancer and diabetes. Differences are likely to be due to factors not 
controlled for such as demographics, socioeconomics, practice infrastructure, and 
community.
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ARE INCREMENTAL BENEFITS FROM MEDICAL CARE DECREASING? AN 
ANALYSIS OF QALY GAINS OVER TIME
Greenberg D, Cohen JT, Neumann PJ
Tufts Medical Center, Boston, MA, USA
OBJECTIVES: As medical care advances, new and innovative interventions may offer 
more limited beneﬁts compared with existing standard of care, which already include 
important background technologies (e.g., statins, effective chemotherapy). We analyze 
changes in incremental QALY gains over time, as reﬂected in cost-utility analyses 
(CUAs). METHODS: We used the Tufts Medical Center Registry of original CUAs 
published through 2007 (www.cearegistry.org) (N  1704) to determine the year of 
publication, type of disease studied, and the incremental QALYs gained for each 
intervention over a comparator. We used linear regression analysis to examine changes 
in incremental QALYs gained by year of CUA publication. Our analysis is restricted 
to CUAs published between 1995 and 2007. As each CUA may report multiple 
incremental cost-effectiveness ratios (ICER), our primary analysis is restricted to 
studies reporting a single incremental value of QALYs gained. In a secondary analysis 
we analyzed QALY gains in all CUAs. Because the distribution of QALY gains 
reported in CUAs is skewed, we log transformed these gains before conducting the 
regression. RESULTS: We analyzed 614 interventions, resulting in a geometric mean 
(median) gain of 0.13 (0.14) QALYs. The results of the multivariable analysis indicate 
that incremental QALY gains are decreasing by 13% annually (P  0.002). Nonethe-
less, this phenomenon is limited, explaining only 2% of the variation in incremental 
QALYs. When all 2415 ICERs were analyzed, the mean (median) gain was 0.12 (0.12) 
QALYs and QALY gains are decreasing by 19% annually (p  0.0001). Our model, 
